Sign in
CompletedNo phase

Helping People Adhere to Their Varenicline Treatment by Co-creating a Conversational Agent: A Feasibility Study

Key facts

Who runs it
Centre for Addiction and Mental Health
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
40 people enrolled
Started
1 Jun 2024
Ended
5 May 2025
Type of study
Interventional
Treatments tested
  • Varenicline healthbot
Record updated
31 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Treatment-seeking smokers who are willing to start taking varenicline and continue it for 12 weeks, and set a quit date in the next 30 days
  • Smoke cigarettes daily (10 or more cigarettes a day)
  • Age ≥ 18 years
  • Speak/read English
  • Have a smartphone with data plan
  • Report being committed to answering questions during follow-up
  • Live in Ontario

Who cannot take part

  • Have contraindication(s) to varenicline use
  • Are pregnant/planning to become pregnant/breastfeeding
  • Participated in the co-design phase

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this feasibility study is to co-create and evaluate a theory informed, evidence-based, patient-centered healthbot aimed at helping people adhere to their varenicline regimen. The main research questions it aims to answer are:

Read full original descriptionShow less

1. What are the challenges to varenicline adherence and strategies to overcome such challenges from the perspective of service users and service providers? 2. What features of a healthbot would help improve adherence to varenicline? 3. Does a healthbot developed to improve varenicline adherence meet the implementation outcomes and increase medication adherence as well as smoking cessation? The study will be conducted using the Discover Design Build and Test framework.

* In the Discover phase, a literature review, 20 service user interviews, and 20 healthcare provider interviews will help inform the challenges to varenicline adherence, strategies to overcome them using the Capability, Opportunity, Motivation, and Behavior framework, and the ways in which a healthbot might help improve adherence. * In the Design, Build and Test phase, 40 participants will interact with a preliminary healthbot using the Wizard of Oz method, then provide feedback about their experiences in a follow up interview; and team members, including clinicians and researchers, will beta test and validate a more refined healthbot.

In the last phase, a non-randomized single arm feasibility study, 40 participants will interact with the healthbot for 12 weeks and provide feedback about the acceptability, appropriateness, fidelity, adoption, and usability of the healthbot; and researchers will assess participants' medication adherence and smoking status.

The group in the trial

  • Varenicline healthbotTreatment being tested

    While the exact healthbot features will be based on results from the rapid review, interviews and Wizard of OZ testing, the investigators know from the existing literature on medication adherence, and behaviour change interventions, that the healthbot will provide: 1) reminders for varenicline dosing and schedule; 2) information and suggestions on managing known side effects (the most frequently cited reason for varenicline non-adherence is experiencing side effects); 3) answers to questions about medication use (e.g., what to do if a dose is missed); and 4) support to increase participants' motivation to continue their quit attempts. During the next 12 weeks, participants will be reminded by the healthbot to take their varenicline at the appropriate times, and will be able to interact with the healthbot when they want.

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Publications
Record updated
31 March 2026